Zenas BioPharma Inc.与诺诚健华宣布签署许可协议,授予Zenas三项自身免疫候选产品的权益,其中包括BTK抑制剂奥雷巴替尼,该药物正处于多发性硬化症三期临床开发阶段

美股速递
Oct 08, 2025

Zenas BioPharma Inc.与诺诚健华宣布签署许可协议,授予Zenas三项自身免疫候选产品的权益,其中包括BTK抑制剂奥雷巴替尼,该药物正处于多发性硬化症三期临床开发阶段

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10